Brief: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies Of NTX-253 For Schizophrenia
08/10/2026 07:41
BRIEF-Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies Of NTX-253 For Schizophrenia Oct 8 (Reuters) - Addex Therapeutics Ltd ADXN.S:
ADDEX SPIN-OUT NEUROSTERIX COMPLETES PHASE 1 CLINICAL STUDIES OF NTX-253 FOR SCHIZOPHRENIA
ADDEX THERAPEUTICS - NEUROSTERIX COMPLETES PHASE 1 STUDIES OF NTX-253, PLANS PHASE 2 DEVELOPMENT
Source text: ID:nGNX8cHGPc
Further company coverage: ADXN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Addex Therapeutics
See all newsBrief: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies Of NTX-253 For Schizophrenia
NASDAQ RESUMED AT 11:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:24 AM
Switzerland's Addex Therapeutics Q2 net loss narrows on decline in R&D expenses
Brief: Addex Therapeutics Q2 Operating Income CHF -645 Thousand